Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Appointed director
Quarterly results
Director departure
Inv. presentation
China Biologic Products Holdings, Inc. (CBPO) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/20/2021 6-K Quarterly results
03/29/2021 6-K Quarterly results
03/01/2021 6-K Quarterly results
01/25/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"China Biologic Products Holdings, Inc."
01/07/2021 6-K Quarterly results
11/24/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"China Biologic Reports Financial Results for the Third Quarter of 2020",
"China Biologic Third Quarter 2020 Financial Results"
11/19/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"China Biologic Products Holdings, Inc.",
"Agreement and Plan of Merger, by and among China Biologic Products Holdings, Inc., CBPO Holdings Limited and CBPO Group Limited"
08/17/2020 6-K Quarterly results
06/29/2020 6-K Quarterly results
05/20/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"China Biologic Reports Financial Results for the First Quarter of 2020",
"China Biologic First Quarter 2020 Financial Results",
"China Biologic Products Holdings, Inc."
03/12/2020 6-K Quarterly results
11/13/2019 6-K Quarterly results
10/17/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"China Biologic Products Holdings, Inc."
09/24/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"China Biologic Products Holdings, Inc."
09/19/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Annex A Preliminary Non-binding Proposal to Acquire China Biologic Products Holdings, Inc."
08/05/2019 6-K Quarterly results
06/28/2019 6-K Quarterly results
05/15/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Notice of Annual General Meeting of Shareholders and Proxy Statement"
05/10/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "China Biologic Products Holdings, Inc. 2019 Equity Incentive Plan",
"China Biologic Products Holdings, Inc. 2019 Equity Incentive Plan"
05/10/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"China Biologic Reports Financial Results for the First Quarter of 2019"
03/06/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2018"
02/20/2019 6-K Quarterly results
02/04/2019 6-K Quarterly results
01/07/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"China Biologic Products Holdings, Inc."
12/14/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"China Biologic Products Holdings, Inc."
11/01/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"China Biologic Reports Financial Results for the Third Quarter of 2018"
09/21/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
09/04/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
08/28/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"China Biologic Responds to Lawsuit Filed in Cayman Islands by Former Chairman BEIJING, China — August 28, 2018 —China Biologic Products Holdings, Inc. , a leading fully integrated plasma-based biopharmaceutical company in China, today issued the following statement in response to a lawsuit filed against the Company in the Cayman Islands by Mr. David Gao, the former Chairman and CEO of the Company who was terminated for cause: “We deeply regret that Mr. David Gao, acting individually in his personal capacity, has attempted to challenge the completion of the private placement that was announced on August 24. The Company is prepared to fend off meritless lawsuits like this and will take actions to seek actual and punitive damages from Mr. Gao in connection with his ill-intended lawsuit as wel..."
08/27/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Share Purchase Agreement by and among China Biologic Products Holdings, Inc., Beachhead Holdings Limited and Double Double Holdings Limited",
"Share Purchase Agreement by and between China Biologic Products Holdings, Inc. and CITIC Capital MB Investment Limited",
"Share Purchase Agreement by and between China Biologic Products Holdings, Inc. and HH China Bio Holdings LLC",
"Share Purchase Agreement by and between China Biologic Products Holdings, Inc. and PW Medtech Group Limited",
"Investor Rights Agreement by and between China Biologic Products Holdings, Inc. and Beachhead Holdings Limited",
"Investor Rights Agreement by and between China Biologic Products Holdings, Inc. and CITIC Capital MB Investment Limited",
"Investor Rights Agreement by and between China Biologic Products Holdings, Inc. and HH China Bio Holdings LLC"
08/24/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"China Biologic Announces Updates on Unsolicited Acquisition Proposals and Strategic Private Placement BEIJING, China — August 24, 2018 — China Biologic Products Holdings, Inc. , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company’ s board of directors has received a letter dated August 23, 2018 from CITIC Capital MB Investment Limited, an affiliate of CITIC Capital Holdings Limited , withdrawing its preliminary non-binding proposal dated June 11, 2018, with immediate effect. The Company further announced that the Board has unanimously decided to reject the previously announced preliminary non-binding proposal dated August 17, 2018 from the consortium consisting of Feng Tai Global Limited, a company beneficially owned by Mr. David Gao..."
08/21/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"China Biologic Announces Receipt of Competing Non-Binding Acquisition Proposal BEIJING, China — August 21, 2018 — China Biologic Products Holdings, Inc. , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors has received an unsolicited, preliminary non-binding proposal letter from a consortium consisting of Feng Tai Global Limited, a company beneficially owned by Mr. David Gao, the former Chairman and CEO of the Company, GL Sandrose Investment L.P., World Investments Limited and CDH Utopia Limited to acquire all of the outstanding shares of the Company not already owned by the Consortium for US$118 per share in cash . A copy of the proposal letter from the Consortium is attached hereto as Annex A. The Company previously ann..."
08/13/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"China Biologic Products Holdings, Inc."
08/03/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"China Biologic Reports Financial Results for the Second Quarter of 2018",
"Summary translation of the Supplemental Agreement to Strategic Cooperation Agreement to Source Raw Plasma made by and among Xinjiang Deyuan, Guizhou Taibang and Lv Xianzhong"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy